BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 28463150)

  • 1. External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
    Gay HA; Sanda MG; Liu J; Wu N; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal CS; Litwin MS; Kuban DA; Hembroff L; Regan MM; Chang P; ; Michalski JM
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):304-317. PubMed ID: 28463150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for urinary toxicity after iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy.
    Eriguchi T; Yorozu A; Kuroiwa N; Yagi Y; Nishiyama T; Saito S; Toya K; Hanada T; Shiraishi Y; Ohashi T; Shigematsu N
    Brachytherapy; 2016; 15(3):288-295. PubMed ID: 26924022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erectile function after prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL; Kurko BS; Lief JH; Allen ZA
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):437-47. PubMed ID: 15890585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term potency preservation following brachytherapy for prostate cancer.
    Snyder KM; Stock RG; Buckstein M; Stone NN
    BJU Int; 2012 Jul; 110(2):221-5. PubMed ID: 22734475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy.
    Schlussel Markovic E; Buckstein M; Stone NN; Stock RG
    BJU Int; 2018 May; 121(5):774-780. PubMed ID: 29319919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
    Roach M
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study.
    Gay HA; Michalski JM; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal C; Litwin M; Kuban D; Hembroff L; Chang P; Sanda MG;
    Urology; 2013 Dec; 82(6):1363-8. PubMed ID: 24139340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
    Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
    JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erectile function after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Galbreath RW; Stipetich RL; Abel LJ; Lief JH
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):893-902. PubMed ID: 11958881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.
    Okihara K; Yorozu A; Saito S; Tanaka N; Koga H; Higashide S; Kikuchi T; Nakano M
    Int J Urol; 2017 Jul; 24(7):518-524. PubMed ID: 28455847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
    Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
    Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry.
    Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR
    Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Predicting Factors for Commonly Neglected Sexual Side Effects to External-Beam Radiation Therapy for Prostate Cancer.
    Frey A; Pedersen C; Lindberg H; Bisbjerg R; Sønksen J; Fode M
    J Sex Med; 2017 Apr; 14(4):558-565. PubMed ID: 28258954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erectile function after stereotactic body radiotherapy for localized prostate cancer.
    Dess RT; Hartman HE; Aghdam N; Jackson WC; Soni PD; Abugharib AE; Suy S; Desai NB; Zumsteg ZS; Mehra R; Morgan TM; Feng FY; Hamstra DA; Schipper MJ; Collins SP; Spratt DE
    BJU Int; 2018 Jan; 121(1):61-68. PubMed ID: 28710895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.
    Banerji JS; Hurwitz LM; Cullen J; Wolff EM; Levie KE; Rosner IL; Brand TC; LʼEsperance JO; Sterbis JR; Porter CR
    Urol Oncol; 2017 May; 35(5):234-242. PubMed ID: 28110975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
    Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
    Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation.
    McGrath SD; Antonucci JV; Fitch DL; Ghilezan M; Gustafson GS; Vicini FA; Martinez AA; Kestin LL
    Brachytherapy; 2010; 9(2):137-44. PubMed ID: 19850537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer.
    Hollenbeck BK; Wei JT; Sanda MG; Dunn RL; Sandler HM
    Urology; 2004 May; 63(5):946-50. PubMed ID: 15134986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.